Rivaroxaban: shortage, pharmacy cost, Medicare spending, recalls

Whether the FDA lists this drug as in short supply.

1 product being discontinued. A maker has told the FDA it will stop making these. That is one maker leaving, not a shortage of the drug:

• Xarelto, For Suspension, 155 mg (NDC 50458-575-01) (Janssen Pharmaceuticals, posted Sep 18, 2026)

The list changes daily, and it covers the national supply. A pharmacy near you can be out of a drug that is not listed, or have one that is. See today's status.

The national average price retail pharmacies pay to buy it (NADAC).

The lowest-cost generic on file is Rivaroxaban 2.5 Mg Tablet: pharmacies pay about $0.626 each, or $18.79 for 30.

This is not your price. NADAC is the national average that retail pharmacies pay to buy the drug, from the Medicaid survey for the week of Nov 11, 2026. What you pay adds the pharmacy's markup and dispensing fee and depends on your insurance or any discount card. "For 30" is shown only for products priced per tablet or capsule. Brand prices here are before any rebates.

Medicare Part D spending by product, from the latest annual file (2024).

In 2024, Medicare Part D plans and their members paid $6.23 billion for the 1 product below. That is up 33% from $4.70 billion in 2020.

Spending is the gross amount paid at the pharmacy by Part D plans and patients, before manufacturer rebates, which can be large for brand drugs. The same person can use more than one product, so people are not added up across rows. A dash means the file suppresses a small number or has no figure for that year.

Recalls reported to the FDA that name this drug.

The FDA has 3 recall records that name rivaroxaban in the product description (3 Class II).

• 20131
• 20142

Most recent 3

• Class IIAttix Pharmaceuticals

  Nov 14, 2014 · Terminated · #D-882-2015

  Rivaroxaban active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada

  Reason: Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

• Class IIJanssen Ortho L.L.C.

  Sep 17, 2014 · Terminated · #D-0006-2015

  Xarelto (rivaroxaban) Tablets 15 mg per tablet, 5 count bottle, Rx Only, Manufactured by: JOLLC, Gurabo, PR 00778 NDC 50458-578-99

  Reason: Microbial Contamination of Non-Sterile Products: Consumer complaint confirmed microbial contamination in sales sample.

• Class IIAidapak Services, LLC

  Jul 2, 2013 · Terminated · #D-596-2014

  RIVAROXABAN Tablet, 20 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 50458057930

  Reason: Labeling: Label Mixup; RIVAROXABAN Tablet, 20 mg may be potentially mislabeled as VENLAFAXINE HCL, Tablet, 100 mg, NDC 00093738301, Pedigree: W002619, EXP: 6/4/2014.

A recall covers specific lots from one company, not every bottle of the drug. Records include combination products and compounded versions that name this ingredient. Class I is the most serious: use could cause serious harm. Class II may cause temporary or reversible harm. Class III is unlikely to cause harm. To check a bottle, match the lot number on the label. See the live list. Do not stop a medicine because of a recall without asking your pharmacist.